Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$325.40 USD

325.40
1,270,338

+3.49 (1.08%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $324.67 -0.73 (-0.22%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.

Indrajit Bandyopadhyay headshot

mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally

by Indrajit Bandyopadhyay

Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.

Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA

by Zacks Equity Research

FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.

Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

by Zacks Equity Research

Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.

Stock Market News for Aug 6, 2021

by Zacks Equity Research

Benchmarks ended in the green on Thursday, as investors accessed positive weekly jobless claims data and awaited the monthly jobs report on Aug 6.

Stock Market News for Aug 5, 2021

by Zacks Equity Research

The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.

Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.

Stock Market News for Aug 4, 2021

by Zacks Equity Research

Benchmarks closed in the positive territory on Tuesday, as investors ignored the rise in new cases of the delta variant, and instead focused more on the upbeat second-quarter earnings results.

Amgen (AMGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 6.05% and 1.48%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Better-Than-Expected Earnings Push Pre-Markets Higher

by Zacks Equity Research

Better-Than-Expected Earnings Push Pre-Markets Higher

Stock Futures Indicate Higher Opening on Strong Q2 Earnings

by Zacks Equity Research

Stock futures rise in pre-market trade on impressive second-quarter earnings results.

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More

by Kinjel Shah

Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.

AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.

What's in Store for Amgen (AMGN) This Earnings Season?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

by Zacks Equity Research

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NASDAQ100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for QQEW

Sweta Killa headshot

Healthcare ETFs in Focus as Q2 Earnings Unfold

by Sweta Killa

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Sheraz Mian headshot

Top Research Reports for Netflix, Medtronic & AstraZeneca

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Medtronic (MDT), and AstraZeneca (AZN).

Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

by Zacks Equity Research

The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).